Noradrenergic dysfunction and antidepressant treatment response

European Neuropsychopharmacology

Volumn 11, Issue 2, 2001, Pages 163-168

  Corrêa, Humberto ^a,c   Duval, Fabrice ^a   Claude, Mokrani Marie ^b   Bailey, Paul ^b   Tremeau, Fabien ^a   Diep, Than Son ^b   Crocq, Marc Antoine ^a   Castro, Juarez Oliveira ^c   Macher, Jean Paul ^a  

^a Centre Hospitalier de Rouffach   (France)

^b Inst Res Neurosci and Psychiat   (France)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Antidepressant response; Clonidine stimulation test; Major depression; Noradrenergic function

Indexed keywords

AMITRIPTYLINE; CLONIDINE; FLUOXETINE; GROWTH HORMONE; NORADRENALIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; NORADRENERGIC SYSTEM; PREDICTION; PRIORITY JOURNAL;

ADRENERGIC ALPHA-AGONISTS; ADULT; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLONIDINE; DEPRESSIVE DISORDER; FEMALE; FLUVOXAMINE; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; PSYCHIATRIC STATUS RATING SCALES; RADIOIMMUNOASSAY;

EID: 0035062786     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(01)00079-7     Document Type: Article

References (48)

1. Neuroendocrine and receptor binding studies in schizophrenia
2. Multiple hormone responses to clonidine administration in depressed patients and healthy volunteers
3. Prediction of treatment response to selective antidepressants from clonidine and apomorphine neuroendocrine challenges
4. Noradrenaline in depressive reactions
5. Short term treatment of mood disorders with standard antidepressants
6. Growth hormone and other responses to clonidine in patients with endogenous depression
7. The growth hormone response to clonidine in endogenous as compared to reactive depression
8. Effects of the electroconvulsive therapy and desipramine on neuroendocrine responses to the clonidine challenge test
9. Abnormalities of indoleamines in affective disorders
10. Disfunçao noradrenérgica e ansiedade em pacientes com depressao maior
11. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression
12. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants
13. 2-adrenergic pathways play a major role in growth hormone neuroregulation
14. Conceptualization and rationale for consensus definitions of terms in major depressive disorder
15. Growth hormone response to growth hormone releasing hormone and clonidine in depression
16. A rating scale for depression
17. Growth hormone response to clonidine in endogenous depressive patients: Evidence for a trait marker in depression
18. Desensitization of platelet alpha-2-adrenoceptors after short term infusions of adrenoceptors agonists in man
19. Clonidine-induced growth hormone secretion in chronic schizophrenia
20. Effects of clonidine on blood pressure, noradrenaline, cortisol, growth hormone, and prolactin plasma levels in high and low intestinal tone subjects
21. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect
22. Panic disorder and major depression, alcoholism, panic and phobic disorders in families of depressed probands with panic disorders
23. Tricyclic therapy of the DSM-III anxiety disorders: A review with implications for further research
24. Effect of clonidine on growth hormone release in psychiatric patients and controls
25. Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline
26. Catecholamine metabolism, depressive illness, and drug response
27. Basic principles of ROC analysis
28. Clinical and biochemical effects of catecholamine depletion on antidepressant induced remission of depression
29. Growth hormone response to clonidine after recovery in patients with endogenous depression
30. Multihormonal response to clonidine in patients with affective and psychotic symptoms
31. Is there a role for a pure noradrenergic drug in the treatment of depression?
32. Augmentation regimens for depression
33. Psychopharmacology of affective disorders in the 21st century
34. Altered central alpha2-adrenoceptor sensitivity in panic disorder
35. Homeostasis and dysregulation in blood element adrenergic receptors: A model for examining parameters of membrane receptor functioning in human psychiatric populations
36. The catecholamine hypothesis of affective disorders: a review of supporting evidence
37. Growth hormone response to clonidine as a probe of noradrenergic receptor responsiveness in affective disorder patients and controls
38. Growth hormone response to clonidine in obsessive-compulsive patients
39. Overview: Toward a dysregulation hypothesis of depression
40. Role of noradrenergic mechanism in the etiology of the affective disorders
41. The growth hormone response to clonidine in acute and remitted depressed male patients
42. Growth hormone response to clonidine in panic disorder patients
43. Blunted growth hormone response to clonidine in panic disorder patients
44. Endogenous depressions with and without disturbances in the 5-hydroxytryptamine metabolism: a biochemical classification?
45. Growth hormone response to clonidine and the cortisol response to dexamethasone in depressive patients
46. Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison
47. Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group